Chloropyramine, 20 mg/ml 1 ml 5 pcs

Chloropyramine is a blocker of H1-histamine receptors. Its chemical structure is related to ethylenediamine derivatives. Chloropyramine selectively blocks H1-histamine receptors and reduces capillary permeability. It prevents the development and facilitates the course of allergic reactions. It has sedative, antihistamine, m-cholinoblocking and pronounced antipruritic effect. It has moderate antispasmodic and antiemetic activity.

Pharmacokinetics

It is evenly distributed in the body including the central nervous system. Penetrates through the blood-brain barrier. Binding of chloropyramine with blood plasma proteins is 7.9%. Peak binding is noted at pH 6.8-7.4. Therapeutic concentration is maintained for 4-6 hours. It is intensively metabolized in liver.

It is excreted mainly through kidneys with urine as metabolites. Excretion of chloropyramine in children may be faster than in adults.

Indications

Neurodermitis, Insect bites, Allergic conjunctivitis, Allergies, Allergic rhinitis, Dermatitis, Eczema, Skin itching, Pollinosis, Urticaria

Allergic diseases, including:

• hives,
• rhinitis,
• conjunctivitis,
• pollinosis (hay fever),
• serum disease,
• drug allergy,

skin diseases, including:

• eczema,
• contact dermatitis,
• cutaneous itching,
• neurodermatitis,
• toxicoderma.

.

Active ingredient

Chloropyramine

Composition

1 ml of solution for intramuscular and intravenous administration contains:

acting substance:

chloropyramine hydrochloride 20 mg;

auxiliary substance: water for injection.

How to take, the dosage

Intramuscularly or intravenously.

Adults are prescribed 20-40 mg per day (contents of 1-2 ampoules).

Treatment in children begins with a dose of 5 mg (0.25 ml). Further dose increases are limited mainly by the occurrence of side effects.

In children aged 1-12 months, 5 mg (0.25 ml).

In children aged 2-6 years – 10 mg (0.5 ml).

In children aged 7-14 years-10-20 mg (0.5-1 ml).

The daily dose should not exceed 2 mg/kg body weight.

In severe allergies, treatment should be started with an injectable form of chloropyramine. At first it is administered slowly intravenously, then it is switched to intramuscular injection and in the final phase of treatment the tablets are taken orally.

Interaction

It enhances the effect of drugs for general anesthesia, hypnotics, sedatives, tranquilizers, m-cholinoblockers, opioid analgesics, local anesthetics.

Tricyclic antidepressants and MAO inhibitors increase m-cholinoblocking and CNS depressant effects.

Caffeine and phenamine reduce CNS depressant effects.

Concomitant use with ethanol is not recommended (risk of severe CNS depression).

Special Instructions

At the time of treatment, no alcoholic beverages are allowed.

Taking the drug at night may worsen the symptoms of reflux esophagitis.

If during long-term use of the drug there is an unexplained increase in body temperature, laryngitis, pale skin, jaundice, oral mucous membrane ulcers, bruising, unusual and difficult to stop bleeding, a physician should be seen, because prolonged antihistamine therapy may lead to hematopoiesis disorders.

The antihistamines may distort reactions in skin allergy testing, so discontinue use several days before the planned test.

When combined with ototoxic drugs, chloropyramine may mask early manifestations of ototoxicity.

Impact on driving and operating machinery

Patients using chloropyramine are advised to refrain from driving vehicles, operating machinery, and other activities requiring increased concentration and quick psychomotor reactions.

Contraindications

• Individual hypersensitivity to the drug or its components;
• acute attack of bronchial asthma;
• concomitant use of monoamine oxidase inhibitors;
• newborn children (less than 1 month.
• pregnancy and lactation
• with acute gastric ulcer
• prostate hyperplasia
• expressive respiratory failure.